AstraZeneca PLC AZNCF Stock
AstraZeneca PLC Price Chart
AstraZeneca PLC AZNCF Financial and Trading Overview
- AstraZeneca PLC Price Chart
- AstraZeneca PLC AZNCF Financial and Trading Overview
- Valuation Measures
- Trading Information
- Financial Highlights
- Profile of AstraZeneca PLC
- Q&A For AstraZeneca PLC Stock
|AstraZeneca PLC stock price||111.25 USD|
|Previous Close||107.1 USD|
|Bid||0 USD x 0|
|Ask||0 USD x 0|
|Day's Range||109.55 - 111.25 USD|
|52 Week Range||104.5 - 143.9 USD|
|Avg. Volume||2.31K USD|
|Market Cap||173.19B USD|
|Beta (5Y Monthly)||0.129406|
|PE Ratio (TTM)||N/A|
|EPS (TTM)||-0.72 USD|
|Forward Dividend & Yield||2.8 (2.57%)|
|Ex-Dividend Date||August 11, 2022|
|1y Target Est||N/A|
AZNCF Valuation Measures
|Enterprise Value||198.85B USD|
|PEG Ratio (5 yr expected)||N/A|
AstraZeneca PLC Stock Price History
|Beta (5Y Monthly)||0.129406|
|S&P500 52-Week Change||-15.35%|
|52 Week High||143.9 USD|
|52 Week Low||104.5 USD|
|50-Day Moving Average||123.05 USD|
|200-Day Moving Average||123.91 USD|
AZNCF Share Statistics
|Avg. Volume (3 month)||2.31K USD|
|Avg. Daily Volume (10-Days)||4.53K USD|
|% Held by Insiders||0.20%|
|% Held by Institutions||49.25%|
|Short % of Float||N/A|
|Short % of Shares Outstanding||N/A|
Dividends & Splits
|Trailing Annual Dividend Rate||2.9|
|Trailing Annual Dividend Yield||2.70%|
|5 Year Average Dividend Yield||304.00%|
|Last Split Factor|
|Fiscal Year Ends||December 31, 2021|
|Most Recent Quarter (mrq)||June 30, 2022|
|Next Fiscal Year End||December 31, 2023|
|Operating Margin (ttm)||17.07%|
|Return on Assets (ttm)||5.52%|
|Return on Equity (ttm)||-4.83%|
|Revenue (ttm)||44.04B USD|
|Revenue Per Share (ttm)||28.67 USD|
|Quarterly Revenue Growth (yoy)||31.00%|
|Gross Profit (ttm)||27.61B USD|
|Net Income Avi to Common (ttm)||-1252999936 USD|
|Diluted EPS (ttm)||-0.72|
|Quarterly Earnings Growth (yoy)||-34.50%|
|Total Cash (mrq)||4.89B USD|
|Total Cash Per Share (mrq)||3.16 USD|
|Total Debt (mrq)||31.39B USD|
|Total Debt/Equity (mrq)||87.31 USD|
|Current Ratio (mrq)||0.959|
|Book Value Per Share (mrq)||23.197|
Cash Flow Statement
|Operating Cash Flow (ttm)||7.62B USD|
|Levered Free Cash Flow (ttm)||3.99B USD|
Profile of AstraZeneca PLC
|Address||1 Francis Crick Avenue|
|Phone||44 20 3749 5000|
|Full Time Employees||83100|
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Q&A For AstraZeneca PLC Stock
What is a current AZNCF stock price?
AstraZeneca PLC AZNCF stock price today per share is 111.25 USD.
How to purchase AstraZeneca PLC stock?
You can buy AZNCF shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AstraZeneca PLC?
The stock symbol or ticker of AstraZeneca PLC is AZNCF.
Which industry does the AstraZeneca PLC company belong to?
The AstraZeneca PLC industry is Drug Manufacturers—General.
How many shares does AstraZeneca PLC have in circulation?
The max supply of AstraZeneca PLC shares is 1.56B.
What is AstraZeneca PLC Price to Earnings Ratio (PE Ratio)?
AstraZeneca PLC PE Ratio is now.
What was AstraZeneca PLC earnings per share over the trailing 12 months (TTM)?
AstraZeneca PLC EPS is -0.72 USD over the trailing 12 months.
Which sector does the AstraZeneca PLC company belong to?
The AstraZeneca PLC sector is Healthcare.